All‐cause mortality, 6 months1 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in all‐cause mortality, 6 months1 compared with placebo (low certainty).
1 finding from 1 review
Non‐fatal cardiovascular events · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in nonfatal cardiovascular event, 6 months5 compared with placebo (low certainty).
1 finding from 1 review
VTE‐related mortality4 · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in VTE‐related mortalitya compared with placebo (low certainty).
1 finding from 1 review
Recurrent VTEc · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in recurrent VTEc compared with placebo (moderate certainty).
1 finding from 1 review
Major bleedinge · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in major bleedinge compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortalityg · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in all‐cause mortalityg compared with placebo (moderate certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in clinically relevant non‐major bleedingh compared with placebo (low certainty).
1 finding from 1 review
Strokei · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in strokei compared with placebo (low certainty).
1 finding from 1 review
Myocardial infarction · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in myocardial infarction compared with placebo (low certainty).
1 finding from 1 review
Major limb amputation ( · Individuals with peripheral arterial disease
Growth factors showed no clear difference in major limb amputation ( compared with placebo or no therapy (moderate certainty).
1 finding from 1 review
Any limb amputation ( · Individuals with peripheral arterial disease
Growth factors may leads to lower any limb amputation ( compared with placebo or no therapy (low certainty).
1 finding from 1 review
Death ( · Individuals with peripheral arterial disease
Growth factors showed no clear difference in death ( compared with placebo or no therapy (moderate certainty).
1 finding from 1 review
Serious adverse events ( · Individuals with peripheral arterial disease
Growth factors showed no clear difference in serious adverse events ( compared with placebo or no therapy (moderate certainty).
1 finding from 1 review
Any adverse event ( · Individuals with peripheral arterial disease
Growth factors showed no clear difference in any adverse event ( compared with placebo or no therapy (moderate certainty).
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (high certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC probably leads to lower symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC leads to lower symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with placebo (high certainty).
1 finding from 1 review